Left Atrial Appendage Closure Devices Market Size, Share and Trends 2024 to 2034

Left Atrial Appendage Closure Devices Market Size and Forecast 2024 to 2034

The global left atrial appendage closure devices market size is projected to be worth around USD 7.01 billion by 2034 from USD 1.87 billion in 2024, at a CAGR of 14.12% from 2024 to 2034. The North America left atrial appendage closure devices market size reached USD 720 million in 2023. The rising prevalence of atrial fibrillation and rising government initiatives contribute to the growth of the market. The growing technological advancement is also promoting the growth of the market.

Left Atrial Appendage Closure Devices Market Key Takeaways

• North America dominated the left atrial appendage closure devices market with the largest market share of 47% in 2023.
• Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2034.
• By product, the endocardial LAA devices segment generated the highest market share of 84% in 2023.
• By product, the epicardial LAA devices segment is expected to be growing significantly during the forecast period.
• By procedure, the percutaneous segment dominated the market in 2023.
• By procedure, the surgical segment is estimated to be the fastest-growing during the forecast period.
• By end-use, the hospitals segment contributed more than 71% of market share in 2023.
• By end-use, the ambulatory surgical centers segment is anticipated to be the fastest-growing during the forecast period.

U.S. Left Atrial Appendage Closure Devices Market Size and Growth 2024 to 2034

The U.S. left atrial appendage closure devices market size was exhibited at USD 540 million in 2023 and is projected to be worth around USD 2.36 million by 2034, poised to grow at a CAGR of 14.34% from 2024 to 2034.

North America dominated the left atrial appendage closure devices market in 2023. Rising atrial fibrillation incidences and increasing senior population contribute to the growth of the market in the North American region. Left atrial appendage management is critical because atrial fibrillation increases the risk of heart attack; the availability of leading medical device manufacturers and robust focus on R&D contribute to the growth of the market in the North American region. A high rate of advanced medical procedures, a broad network of specialized cardiac centers, and the strong healthcare system of the United States help the market’s growth.

• In November 2023, Medtronic launched a left atrial appendage closure device, ‘Penditure.’ The device is designed in the United States to close the LAA (left atrial appendage) of heart patients who suffer from cardiac surgeries.

Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2034. The increasing healthcare systems, increasing healthcare expenditure, and rising awareness about the importance of left atrial appendage closure devices. The company initiatives support the growth of the left atrial appendage closure devices market in the Asia Pacific region. Collaborative acquisition, agreements, geographical expansions, and investment in products by key players help the market’s growth.

• In September 2023, in the Indian healthcare space, medical technology in cardiac care is gaining traction. India has indigenously developed AI (artificial intelligence) and ML (machine learning) based cardiac care tools. These tools are used in mitral valve replacements and repairs and in left atrial appendage closure (LAAC).

According to data from the Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals, Indian medical device market export and import data for the past two financial years:

Import of medical devices in the past two financial years:

Export of medical devices in the past two financial years:

Market Overview

The left atrial appendage closure devices market refers to buyers and sellers of left atrial appendage closure (LAAC) devices, which are medical devices designed to prevent blood clots from forming the LAA (Left atrial appendage) of the heart that may cause stroke in patients with atrial fibrillation. LAA Closure procedure that closes or blocks the opening of left atrial appendages to keep blood clots from going into or leaving their bloodstreams. The benefits of left atrial appendage closure devices include helping to reduce the risk of stroke, stopping blood thinners use, etc.

Left Atrial Appendage Closure Devices Market Growth Factors

• The benefits of left atrial appendage closure (LAAC) include helping to reduce the risk of stroke, stopping blood thinners use, etc.
• It also includes having the procedure done at the time of heart surgery for other issues and having minimally invasive procedures for an LAAC device.
• For eligible patients, the left atrial appendage closure device is an alternative to blood thinners, which helps the left atrial appendage closure devices market growth.
• Clinical trial data of initial and mid-term suggests that left atrial appendage closure is safe, with lower intracranial bleeding and a complete clinical advantage that performs to be non-inferior to oral anticoagulation.

What are the benefits of AI in the Left Atrial Appendage Closure Devices?

The use of AI in left atrial appendage closure devices offers significant benefits, mainly in reducing stroke risks and treating atrial fibrillation. The benefits of AI in left atrial appendage closure devices also include improving pre-procedural imaging and planning by providing more precise and detailed images of heart anatomy. AI algorithms can analyze patient data to predict the best treatment options and contribute to the growth of the left atrial appendage closure devices market. AI can help in personalized treatment, improved safety and efficacy, the time required for the procedure can be reduced, and post-procedural monitoring ensures that any signs of complications are detected early.

• In August 2023, the Acuson Origin, a committed cardiovascular ultrasound system with new AI (artificial intelligence) features, was launched by Siemens Healthineers at the annual meeting of the ESC (European Society of Cardiology) in Amsterdam. The new therapies are helpful in the left atrial appendage closure devices and in treating patients who suffer from tricuspid regurgitation.

Market Scope

Market Dynamics

Driver

Growing prevalence of atrial fibrillation

The growing prevalence of atrial fibrillation causes include hereditary, obesity, alcohol consumption, heart diseases, uncontrolled high blood pressure, older age higher risk, obesity, viral infections, lung and kidney diseases, sleep disorders, stress, previous heart surgeries, abnormal heart valves, viral infections, high blood pressure, heart attacks, etc. needs the left atrial appendage closure devices which driving the growth of the left atrial appendage closure devices market.

Restraint

High cost and availability of alternative technologies

The high cost and availability of alternative technologies for LAAC devices can hamper the growth of the left atrial appendage closure devices market. The left atrial appendage closure device risks also include infection, abnormal heart rhythm, cardiac arrest, chest pain, bleeding, a reaction to anesthesia, a problem with the device itself, risk of stroke, risk of peripheral vascular damage, risk of tamponade that requires urgent drainage or blood transfusion, blood clots forming on the device, damage to structures in the heart, incomplete closure of the left atrial appendage, etc.

Opportunity

Research and development

The research and development in left atrial appendage closure devices, there is an opportunity for the left atrial appendage closure devices market. Advances in data analysis and technology for more effective research, increasing demand for research in emerging fields, and collaborative cross-disciplinary approaches and research initiatives contribute to the growth of the market in the future.

Product Insights

The endocardial LAA devices segment dominated the left atrial appendage closure devices market in 2023. Endocardial LAA devices are easier to use and are also known as watchman devices. The presence of a broad range of products and a strong product line contribute to the market’s growth. It helps to reduce the thromboembolic stroke in atrial fibrillation. The benefits of freedom from lifestyle risks because of blood thinner risks and the worry that comes along with them eliminate stroke risks without long-life blood thinner medications, prevent blood clots, etc. The endocardial LAA devices are permanent implants, one-time, minimally invasive, and safe.

In September 2023, the United States Food and Drug Administration approved the new generation WATCHMAN FLX Pro LAAC (Left Atrial Appendage Closure) Device, which was announced by Boston Scientific Corporation. The new WATCHMAN Technology is used to reduce stroke risk in patients with NVAF ( Non-vascular atrial fibrillation) who need an alternative to oral anticoagulation therapy.

The epicardial LAA devices segment is expected to grow significantly during the forecast period. The epicardial LAA devices are also known as lariat devices. The benefits of epicardial LAA devices are decreased medical visits and blood tests after the procedure, minimum discomfort from the procedure, shorter recovery time, lowered risk of stroke, etc., contributing to the growth of the left atrial appendage closure devices market. There is no need for short-term anticoagulation therapy.

Procedure Insights

The percutaneous segment dominated the left atrial appendage closure devices market in 2023. The percutaneous left atrial appendage closure is a transcatheter procedure where a device is implanted into a left atrial appendage to exclude it from systemic circulation. The benefits of percutaneous left atrial appendage closure devices include lower risks of stroke by preventing the forming of blood clots and leaving the left atrium of the heart. In this procedure, it doesn't treat atrial fibrillation itself. Thereafter, we may still need to use treatments and take other medicines to keep the heart in a normal rhythm.

• In February 2023, a simple device that holds sutures more safely in place for closure of percutaneous wound sites at the time of structural heart, cardiac electrophysiology, and vascular surgical procedures was launched by Ra Medical Systems, Inc.

The surgical segment is estimated to be the fastest-growing during the forecast period. The benefits of surgical left atrial appendage closure procedures include minimally invasive procedures for LAA closure, the ability to stop taking blood thinners, reduced risk of stroke, etc., contributing to the growth of the left atrial appendage closure devices market.

• In August 2024, an AtriClip device to exclude and electrically isolate the left atrial appendage (LAA) at the time of cardiac surgery was designed by Mason, Ohio-based AtriCure.

End-use Insights

The hospitals segment dominated the left atrial appendage closure devices market in 2023. Left atrial appendage closure devices play an important role in hospitals for the treatment of risks of stroke in patients. It does not require blood tests or restrictions on drinking or food and reduces the risk of excessive bleeding that exists with the use of thinners. The benefits of left atrial appendage closure device use in hospitals include prescription drugs, mental health services, maternity and newborn care, emergency services, access to the latest treatments, research and innovation, technological advancements, patient-centric approach, nursing excellence, and medical expertise.

• In June 2024, at the University Hospitals (UH), with great success, a novel approach to heart bypass surgery is now offered to patients. The UH uses the Da Vinci Robot to perform cardiac surgeries like pericardial resection, ligation of the left atrial appendage, ablation for atrial fibrillation, epicardial lead placement, and minimally invasive coronary artery bypass grafting.

The ambulatory surgical centers segment is anticipated to be the fastest-growing during the forecast period. The left atrial appendage closure devices play a significant role in ambulatory surgical centers, which contribute to the growth of the left atrial appendage closure devices market. These ambulatory surgical centers offer patients many benefits over traditional hospital-based surgical procedures, including lower chances of infectious disease exposure, lower costs, and shorter wait times.

Left Atrial Appendage Closure Devices Market Companies

• Occlutech
• Nanjing YDB Technology Co., Ltd
• LifeTech Scientific (Shenzhen)
• Johnson & Johnson
• Cardia, Inc.
• Boston Scientific Corporation
• ArtiCure, Inc.
• Abbott Laboratories
• Lepu Medical Technology (Beijing) Co. Ltd.
• Biosense Webster, Inc.
• Sentreheart, Inc.
• Aegis Medical Group
• Mentice
• Curvo Labs, Inc.

Recent Developments

• In February 2024, the investigational devices designed by a global leader in cardiac arrhythmia treatment, Biosense Webster, Inc., and part of Johnson & Johnson MedTechi, for the LAAX (Left Atrial Appendage Elimination) to reduce the risk of stroke in patients with non-valvular atrial fibrillation as a part of its IDE (investigational device exemption) study.
• In August 2024, the venous closure device named Vascade MVP XL mid-bore venous closure system was launched by Haemonetics full market. This system is used in the left atrial appendage closure (LAAC), cryoablation, and pulsed-field ablation. The device is available to hospitals in the United States to promote rapid homeostasis.

Segments Covered in the Report

By Product

• Endocardial LAA Devices
• Epicardial LAA Devices

By Procedure

• Percutaneous
• Surgical

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Other End Users

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa